Results for "Entresto"

Pharmaceutical giant Novartis is back on a growth trajectory, skillfully rejuvenating its business despite significant losses from its off-patent heart medication Entresto. The company is expected to face a more turbulent second half of the year on the stock market.

Novartis reported first-quarter earnings that fell short of sales and profit estimates, primarily due to the impact of generic competition on its drug Entresto. Despite the miss, the company reaffirmed its growth outlook for 2026.